Added to YB: 2026-09-23
Pitch date: 2026-09-17
IPHA [neutral]
Innate Pharma S.A.
-8.33%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Market Cap
EUR 146.5M
Pitch Price
EUR 1.92
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.34
P/E
-3.05
EV/Sales
15.89
Sector
Biotechnology
Category
special_situation
Innate Pharma (IPH France): Clinical catalysts approach
IPHA (update): Innate Pharma enters a catalyst-heavy period with cash runway through Q1 2028 after Sobi’s $75M upfront payment and a €30M capital increase. Phase III PACIFIC-9 results for partnered monalizumab are a particularly significant year-end event, alongside initial Phase I data for IPH4502 and lacutamab’s accelerated-approval path. The stronger financing reduces near-term capital needs, but biotechnology development remains dependent on clinical outcomes, and confirmatory-trial spending is expected to rise.
Read full article (2 min)